Pioneering the Science of Epigenetics™
A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. Our technologies and products are making studies possible that were not imaginable just a few years ago. Our innovation is a direct result of the scientific power associated with EpiCypher. Our renowned chromatin researchers possess expertise and unique insight into epigenetics that benefit our customers in ways other companies cannot.
Arising from an abundance of demand for high quality products from the laboratories of Mark Bedford, Brian Strahl, and Or Gozani EpiCypher was founded on January 18, 2012 as a spin-out from University of North Carolina at Chapel Hill. Starting with the groundbreaking and proprietary histone peptide array platform, EpiGold™, EpiCypher has developed a wide portfolio of best in class products. EpiCypher's mission is to develop products to enable researchers to complete experiments that are not otherwise possible.
I recently worked with EpiCypher and their modified histone peptides to help us address a reviewer’s comments on a manuscript submission. My experience with their service, products and technical support was outstanding! The peptides were shipped in a timely manner; they were cost-effective and easy to use. The availability of matched sets of peptides that range from unmodified through multivalent modifications allowed for the direct assessment of selectivity and specificity without the added cost of multiple syntheses. The experiment worked flawlessly, thus allowing us to resubmit with a quick turnaround. I look forward to continuing my relationship with EpiCypher and their superior products.
Professor, Department of Radiation Oncology, Emory University School of Medicine
Leader, Cancer Genetics and Epigenetics Program
Winship Cancer Institute of Emory University